Latest Ratios: P/E Ratio -51.4x · EV/EBITDA N/A · ROE -14.2%. (2018–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $4.8B | $3.8B | $440M | $462M | $367M | $179M | — | — | — |
| Enterprise Value | $4.2B | $3.2B | $280M | $383M | $225M | $131M | — | — | — |
| P/E Ratio → | -51.41 | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | 178.65 | — | — | — |
| P/B Ratio | 4.90 | 3.74 | 1.27 | 1.81 | 1.32 | 1.11 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | 130.95 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | 100.0% | — | — | — |
| Operating Margin | — | — | — | — | — | -4986.0% | — | — | — |
| Net Profit Margin | — | — | — | — | — | -5015.8% | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -14.2% | -14.2% | -29.6% | -33.9% | -27.6% | -43.8% | -67.5% | -131.2% | -20.5% |
| ROA | -13.9% | -13.9% | -28.1% | -32.5% | -26.5% | -38.5% | -50.5% | -121.8% | -19.9% |
| ROIC | -24.7% | -24.7% | -42.2% | -49.5% | -37.6% | -62.7% | -440.2% | -1049.8% | -343.2% |
| ROCE | -16.2% | -16.2% | -33.7% | -38.3% | -28.2% | -43.2% | -83.7% | -132.9% | -21.3% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.19 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.52 | -0.46 | -0.31 | -0.51 | -0.30 | -0.90 | -0.67 | -0.95 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — |
Net cash position: cash ($525M) exceeds total debt ($919000)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 62.41 | 62.41 | 23.14 | 22.39 | 33.68 | 24.48 | 3.98 | 4.49 | 37.25 |
| Quick Ratio | 62.41 | 62.41 | 23.14 | 22.39 | 33.68 | 24.48 | 3.98 | 4.49 | 37.25 |
| Cash Ratio | 62.09 | 62.09 | 22.89 | 22.06 | 33.43 | 24.34 | 3.28 | 3.97 | 36.58 |
| Asset Turnover | — | — | — | — | — | 0.01 | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $93M | $80M | $71M | $36M | $25M | $25M | $25M | $24M |
Clinical trial execution risk
According to recent market data, TERN trades at a price-to-book ratio of 4.90, which suggests that investors are pricing the company based on the long-term potential of its clinical pipeline rather than current tangible assets or any near-term earnings generation capability.
The absence of meaningful P/E or P/S multiples underscores the pre-revenue nature of the business, where valuation is driven by the probability-weighted success of clinical assets. Investors should monitor whether this premium valuation holds as the company approaches critical data readouts, as any clinical disappointment could lead to significant multiple compression.
Based on reported financial figures, TERN's ROIC has remained consistently negative, reaching -6.7% in 2025Q4, which is a direct consequence of the company's heavy investment in clinical development without the offsetting revenue streams required to generate positive returns on invested capital.
The persistent negative ROIC is expected for a clinical-stage biotech firm, but it highlights the high cost of capital required to sustain its multi-asset pipeline. This trend warrants further investigation into whether the company's capital allocation strategy will eventually yield a positive return once commercialization begins.
As reported in recent SEC filings, TERN maintains a current ratio of 62.41, indicating a highly liquid position that provides a substantial buffer to fund ongoing research and development activities through the projected 2027 horizon without immediate reliance on external debt markets.
This liquidity profile is exceptionally strong for a pre-revenue company, effectively mitigating near-term insolvency risk. However, investors should monitor the rate of cash depletion, as the high current ratio is primarily a function of cash reserves rather than operational efficiency.
As reported in financial statements, TERN's P/B ratio of 4.90 sits below the levels seen in peers like Madrigal Pharmaceuticals, suggesting that the market may be applying a discount to TERN's multi-mechanism approach compared to more specialized, single-asset competitors in the metabolic space.
The valuation gap appears to reflect the market's assessment of execution risk across TERN's diverse pipeline. While this may indicate an undervaluation if TERN's small-molecule platform proves superior, it also suggests that the market is currently prioritizing the more advanced clinical progress of its direct competitors.
Based on standard financial analysis, the use of P/E ratios to evaluate TERN is fundamentally flawed, as the company's negative earnings are a structural feature of its R&D-heavy business model rather than an indicator of operational failure or poor management performance.
Investors should instead focus on cash runway and clinical milestone progress, as traditional profitability metrics obscure the value creation occurring within the R&D pipeline. Relying on P/E ratios in this context may lead to erroneous conclusions regarding the company's long-term viability and investment attractiveness.
Includes 30+ ratios · 8 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying TERN stock.
Terns Pharmaceuticals, Inc.'s current P/E ratio is -51.4x. This places it at the 50th percentile of its historical range.
Terns Pharmaceuticals, Inc.'s return on equity (ROE) is -14.2%. The historical average is -46.0%.
Based on historical data, Terns Pharmaceuticals, Inc. is trading at a P/E of -51.4x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.